Teva Gets EU Nod for Neulasta ‘Biobetter’

Teva’s own brand drug Lonquex has won EU approval and will compete with Amgen’s Neulasta in the stimulation of white blood cells to treat chemotherapy-induced neutropenia and febrile neutropenia.
Pharma Times